Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets open firm
Tue, 11 Mar 09:30 am

Asian stock markets have opened the day in the green with the stock markets in Japan (up 0.6%) and Singapore (up 0.4%) leading the gains. The Indian share markets have opened the day on a firm note as well. Among the sectoral indices, banking and power sector indices are leading the gains. However, metal and information technology indices are trading weak.

The Sensex today is up by around 45 points (0.2%), while the NSE-Nifty is up by about 13 points (0.2%). The mid and small cap stocks have also opened in the green with the BSE Mid Cap and BSE Small Cap indices up by around 0.6% each. The rupee is currently trading at Rs 60.88 to the US dollar.

Auto stocks have opened the day mainly in the green with Tube Investments, Maharashtra Scooters and Bajaj Auto leading the gains. As per a leading financial daily, nearly 600 permanent employees of auto major Tata Motors are understood to have accepted an early retirement offer (ERO). The company had launched this offer earlier this year in a bid to reduce the workforce and cut costs at a time when the company's domestic operations have been under strain for several quarters. The departing employees include both executives as well as workers across six plants and regional offices. It must be noted that Tata Motors has total workforce strength of about 30,000 people.

MNC Pharma stocks have opened the day mainly in the green with GlaxoSmithKline Pharmaceuticals (GSK Pharma) and Pfizer Ltd leading the gains. As per a leading financial daily, British healthcare conglomerate GlaxoSmithKline Plc has successfully completed the voluntary open offer worth Rs 63.89 bn to acquire additional 24.33% stake in its Indian subsidiary GSK Pharma from public shareholders. This has helped the British drug maker to increase its shareholding in GSK Pharma to 75%. Against the proposal to buy 20.6 million shares at a price of Rs 3,100 per share, more than 23.2 million shares were tendered by shareholders. It must be noted that the British parent firm has stated that it intends to keep its Indian subsidiary listed on the stock exchanges.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.